Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16429107 | 0.88 | CHRNB2 (0.42) | — | |
| SCHEMBL16429268 | 0.87 | CHRNB2 (0.41) | SIGMAR1KCNH2 | |
| SCHEMBL16428940 | 0.86 | MMP2 (0.40) | KCNH2 | |
| Hydrochloric Acid SCHEMBL16246761 | 0.85 | MMP2 (0.40) | — | |
| Hydrochloric Acid SCHEMBL16247177 | 0.85 | MMP2 (0.40) | — | |
| SCHEMBL16428817 | 0.85 | ERAP2 (0.35) | KCNH2 | |
| SCHEMBL16429158 | 0.85 | SIGMAR1 (0.44) | SIGMAR1 | |
| SCHEMBL16429223 | 0.85 | SIGMAR1 (0.44) | SIGMAR1 | |
| SCHEMBL16264591 | 0.83 | CHRM2 (0.63) | CHRM2MAOASIGMAR1MEN1KMT2A | |
| SCHEMBL18223040 | 0.83 | CHRNA1 (0.39) | CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10440955-B2 | Methods comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180125070-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | THE UNIVERSITY OF UTAH | 2018-05-10 | — | — | US | disclosed |
| US-9839219-B2 | Compositions comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160330962-A1 | COMPOSITIONS COMPRISING A BIOCIDAL POLYAMINE | CURZA GLOBAL, LLC | 2016-11-17 | — | — | US | disclosed |
| US-9439433-B2 | Compositions and methods comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150038512-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | THE UNIVERSITY OF UTAH | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160330962-A1 | COMPOSITIONS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMS, SMOX | CHRM2 3917/4885MAOA 116/4885SIGMAR1 1551/4885 |
| US-10440955-B2 | Methods comprising a biocidal polyamine | SRM, SMOX, SMS | CHRM2 3986/4885MAOA 116/4885SIGMAR1 1642/4885 |
| US-20180125070-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMOX, SMS | CHRM2 3947/4885MAOA 110/4885SIGMAR1 1771/4885 |
| US-20150038512-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMOX, SMS | CHRM2 3947/4885MAOA 110/4885SIGMAR1 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.